No. of depression patients exceeds 1m in 2022
Seoul subway fare to rise 12% beginning Saturday
Korean Air to submit new merger plan to ease antitrust concerns
Korea to begin experiment with central bank digital currency
Races tighten in Seoul as parties battle for Assembly control
6-year-old Uzbek girl found dead in Daegu
Star lecturers, hagwon probed over buying Suneung questions
US House votes to remove Speaker Kevin McCarthy
Culture minister nominee warns celebrities to be cautious over political speech
Actor Park Eun-bin opens 28th Busan International Film Festival’s opening ceremony
Samsung Biologics wins record Pfizer dealBy Shim Woo-hyun
Published : June 8, 2023 - 16:09
Samsung Biologics said Thursday the company won a $411.3 million contract manufacturing deal from Pfizer to produce the US-based pharmaceutical giant’s biosimilar products.
Even though the company didn’t specify the product name, industry watchers predict that the deal is highly likely to involve producing Pfizer’s Abrilada, a biosimilar to the autoimmune disease drug known as Humira.
In the statement, Samsung said it will produce Pfizer’s multiple biosimilar products with indications for tumor and inflammatory diseases.
Abrilada is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions. Pfizer is currently seeking to win an interchangeability designation for Abrilada and plans to launch the biosimilar as early as July in the US.
Samsung Biologics added Pfizer’s products will be produced at the company’s recently finished fourth plant.
Other details of the deal, including the contract period, were not revealed immediately. Samsung only said it is a “long-term” contract.
According to Samsung Biologics, the latest deal is the largest of its kind for the Korean firm, followed by its previous record deal worth $359.7 million with AstraZeneca.
It also marks the second deal with Pfizer. In March this year, the company signed a 241 billion won ($184 million) deal to manufacture Pfizer’s single product.
"This partnership is a great example of Pfizer's confidence in the Korean pharmaceutical industry, and we are pleased to continue and expand our strategic partnership with Samsung Biologics to bring better treatment options to patients around the world," said Mike McDermott, Pfizer’s chief global supply officer.
Meanwhile, Samsung Biologics announced on Monday (local time) at the 2023 BIO International Convention that the company will start operating its fifth plant in April 2025, five months earlier than its original schedule, in order to meet a rush of orders from global big pharma companies.
Upon the plant's full completion, the company will maintain its global leadership in biomanufacturing capacity with a total of 784,000 liters.
Pentagon chief renews support for Japan's 'counterstrike' capabilities amid N. Korean threats
S. Korean experts to inspect Japan water release
PM orders measures to prevent public opinion manipulation on web portals